Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMW1YK3)

Drug Name

Lysine Nz-Carboxylic Acid Drug Info

Synonyms

Lysine Nz-Carboxylic Acid; N(6)-carboxylysine; N(6)-carboxy-L-lysine; (2S)-2-amino-6-(carboxyamino)hexanoic acid; N~6~-carboxy-L-lysine; SCHEMBL357483; CHEBI:43575; ZINC6753301

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 17754054
ChEBI ID: CHEBI:43575
TTD Drug ID: DMW1YK3

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Investigative Drug(s)

Clinical Trial Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting Mycobacterium Biosynthetic alanine racemase (MycB alr)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cycloserine	DMT1I52	Bacterial infection	1A00-1C4Z	Approved	[1]
Acetate Ion	DMD08RH	Discovery agent	N.A.	Investigative	[1]
Pyridoxamine-5'-Phosphate	DMQ6POC	Discovery agent	N.A.	Investigative	[1]
Propionate	DM0O8N6	Discovery agent	N.A.	Investigative	[2]
Pyridoxyl-N,O-Cycloserylamide-5-Monophosphate	DM7AW0X	Discovery agent	N.A.	Investigative	[1]
N-(5'-Phosphopyridoxyl)-D-Alanine	DM3FCAI	Discovery agent	N.A.	Investigative	[1]
Pyridoxyl-Alanine-5-Phosphate	DMUVCWY	Discovery agent	N.A.	Investigative	[1]
Propanoic Acid	DM9TN2W	Discovery agent	N.A.	Investigative	[1]
3-fluorovinylglycine	DMECBLA	Discovery agent	N.A.	Investigative	[3]
------------------------------------------------------------------------------------


⏷ Show the Full List of 9 Drug(s)

Drug(s) Targeting Plasmodium Dihydroorotase (Malaria dho)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Orotate	DMMB29S	Discovery agent	N.A.	Investigative	[4]
Dihydroorotate	DM76BGZ	Discovery agent	N.A.	Investigative	[1]
5-Fluoro orotate	DMLSC10	Discovery agent	N.A.	Investigative	[4]
5-bromo orotate	DM0HCG6	Discovery agent	N.A.	Investigative	[4]
N-Carbamoyl-L-Aspartate	DMJ13TR	Discovery agent	N.A.	Investigative	[1]
5-iodo orotate	DMDKFIO	Discovery agent	N.A.	Investigative	[4]
5-methyl orotate	DMYNFIP	Discovery agent	N.A.	Investigative	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 7 Drug(s)

Drug(s) Targeting Cyclin-dependent kinase 2 (CDK2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
R-roscovitine	DMSH108	Non-small-cell lung cancer	2C25.Y	Phase 2	[5]
Ro 31-7453	DM83QCL	Solid tumour/cancer	2A00-2F9Z	Phase 2	[6]
PHA848125	DMS2Q9G	Thymic cancer	2C27	Phase 2	[7]
TG02	DMZFIGQ	Anaplastic astrocytoma	2A00.0	Phase 1/2	[8]
NUV-422	DMQJQNT	Malignant glioma	2A00.0	Phase 1/2	[9]
RGB-286638	DMEGOQP	Haematological malignancy	2B33.Y	Phase 1	[10]
FN-1501	DM7BMD6	Solid tumour/cancer	2A00-2F9Z	Phase 1	[11]
AG-024322	DMY4WVK	Solid tumour/cancer	2A00-2F9Z	Phase 1	[5]
PHA-793887	DM2Y4FG	Solid tumour/cancer	2A00-2F9Z	Phase 1	[12]
SNS-032	DMEITAS	Solid tumour/cancer	2A00-2F9Z	Phase 1	[13]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Cyclin-dependent kinase 2 (CDK2)	TT7HF4W	CDK2_HUMAN	Inhibitor	[1]
Mycobacterium Biosynthetic alanine racemase (MycB alr)	TT6TMZU	ALR_MYCSM	Inhibitor	[1]
Plasmodium Dihydroorotase (Malaria dho)	TT09NOX	A9CSR1_PLAFA	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2	Molecular dynamics studies of alanine racemase: a structural model for drug design. Biopolymers. 2003 Oct;70(2):186-200.
3	Mechanism-based inactivation of alanine racemase by 3-halovinylglycines. J Biol Chem. 1991 Nov 15;266(32):21657-65.
4	Antimalarial activity of orotate analogs that inhibit dihydroorotase and dihydroorotate dehydrogenase. Biochem Pharmacol. 1992 Mar 17;43(6):1295-301.
5	Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
6	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
7	Identification of N,1,4,4-tetramethyl-8-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-4,5-dihydro-1H-pyrazolo[4,3-h]quinazoline-3-carboxamide (PHA-848125), a potent, orally available cyclin dependent kinase inhibitor. J Med Chem. 2009 Aug 27;52(16):5152-63.
8	Preclinical metabolism and pharmacokinetics of SB1317 (TG02), a potent CDK/JAK2/FLT3 inhibitor. Drug Metab Lett. 2012 Mar;6(1):33-42.
9	ClinicalTrials.gov (NCT04541225) Phase 1/2 Dose Escalation, Safety, Pharmacokinetics, and Efficacy Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors. U.S.National Institutes of Health.
10	Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
11	Discovery of 4-((7H-Pyrrolo[2,3-d]pyrimidin-4-yl)amino)-N-(4-((4-methylpiperazin-1-yl)methyl)phenyl)-1H-pyrazole-3-carboxamide (FN-1501), an FLT3- and CDK-Kinase Inhibitor with Potentially High Efficiency against Acute Myelocytic Leukemia. J Med Chem. 2018 Feb 22;61(4):1499-1518.
12	A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
13	Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood. 2009 May 7;113(19):4637-45.